Tests atebimetinib with chemotherapy in advanced pancreatic cancer
Tests atebimetinib added to chemotherapy in adults with metastatic pancreatic cancer.
Plain-language title generated from the registry record
Registry title: Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Key facts
- Where
- Hamburg, Heilbronn, Muenchen, Munich, and Riesa, GermanySee the 5 sites
- Phase
- Phase 3
Where in Germany
- Katholisches Marienkrankenhaus gGmbHHamburg, GermanyTaking people
- SLK-Kliniken Heilbronn GmbHHeilbronn, GermanyTaking people
- Technische Universität München - Klinikum Rechts der IsarMuenchen, GermanyTaking people
- LMU Klinikum Muenchen AöRMunich, GermanyTaking people
- Elblandkliniken Stiftung & Co.KGRiesa, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Immuneering Corporation
- Trial code
- NCT07562152EU 2026-525617-31-00
- Record updated
- 6 November 2026
- Original description
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.Read full original descriptionShow less
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Inclusion: Must be ≥18 years of age; Must have confirmed diagnosis according to AJCC staging as follows:; Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Participants must be treatment naive as follows:; First-line PDAC participants will have received no previous systemic anti-cancer therapy; Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria; Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values.
Exclusion: Inability to swallow oral medications; Participants with only locally advanced disease; Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma; Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases.